Dermal Filler Comparison Guide by Type, Area & Longevity

HA fillers dominate because they're reversible, predictable, and carry low regulatory friction. The key variable is crosslinking density and particle size. Tightly crosslinked products (Juvéderm Ultra XC, Restylane Lyft) last 9–12 months and hold structure in high-movement zones; loosely crosslinked or uncrosslinked HA (Juvéderm Ultra, Restylane Refyne) lasts 6–9 months and integrates more naturally in fine-line areas. Allergan Aesthetics and Galderma dominate this space. Cost per syringe typically ranges from $8–$15 at wholesale depending on your rebate tier and volume commitments. HA's reversibility with hyaluronidase is a clinical and medicolegal asset—patients value the safety net. The trade-off: HA requires touch-ups 2–3 times yearly, driving patient lifetime value but also appointment friction. Consider your patient retention and scheduling capacity when building HA depth.

Poly-L-lactic acid (Sculptra) and calcium hydroxylapatite (Radiesse) work by triggering collagen deposition, not volume replacement. Sculptra lasts 2+ years; Radiesse 12–18 months. Both require 2–4 treatment sessions spaced weeks apart, and results emerge gradually over months—a harder patient education lift but a powerful retention tool. Wholesale cost is higher ($25–$35 per syringe equivalent) but amortized over 24 months, the per-month cost rivals HA. Biostimulators excel in midface volume loss, jawline definition, and hand rejuvenation where you want structural remodeling, not just filler. They're less suitable for lips and tear troughs (risk of granulomas, visibility of particles). Evolus markets Nuvo (PLLA) aggressively; Galderma owns Radiesse. If your patient base skews older or wants fewer appointments, biostimulators justify premium pricing and improve case economics.

Allergan's SKINVIVE by Juvéderm (FDA-approved 2024) is a dilute HA gel designed specifically for neck and décolletage—lower viscosity, superficial placement, 6-month duration. It represents product segmentation: same parent company, different indication, different price point. Galderma's Teosyal and Restylane lines offer multiple crosslink densities within the same family, allowing you to tier by area and patient expectation. Some practices use uncrosslinked HA for lips (softer, more natural migration) and highly crosslinked HA for cheeks (structure, longevity). This requires SKU discipline and staff training but maximizes case value. Emerging biostimulator hybrids (HA + PLLA combinations) are in development; watch regulatory approvals. The economics favor practices that can educate patients on product differences and justify premium pricing for targeted formulations.

Longevity varies by anatomy, not just product. Lips and tear troughs—high-movement, thin-skinned zones—see 40–50% resorption within 6 months; cheeks and jawline see 20–30%. A patient receiving Juvéderm Ultra XC in the cheek may enjoy 12 months; the same product in the lips lasts 7–8 months. This drives your consultation script and pricing: charge for placement difficulty and patient expectation, not just product cost. Biostimulators, which integrate into tissue, show less area-dependent variation—Sculptra in the cheek and hand both last 2+ years. High-movement zones (lips, nasolabial folds) are where HA's reversibility and frequent touch-ups create appointment volume; structural zones (midface, jawline) are where biostimulators and long-acting HA justify premium pricing and reduce patient friction.

Allergan's Alle program and Galderma's Aspire offer volume-based rebates: buy more units, lower per-unit cost. A practice buying 50 syringes/month may pay $12/syringe; one buying 200/month may pay $8. Evolus Rewards operates similarly. Your filler margin depends on volume commitment, payer mix (cash vs. insurance—rare for fillers), and case pricing. A typical cash practice marks up 2.5–3.5x wholesale, so an $8 syringe retails at $20–$28. High-volume practices negotiate harder and accept lower per-case margins for volume. Biostimulators carry higher wholesale cost but also higher retail price ($400–$600 per syringe equivalent vs. $150–$300 for HA), so margin dollars are comparable. Track your inventory turnover: slow-moving SKUs tie up capital. Negotiate rebate tiers based on realistic monthly volume, not aspirational projections.

Start with a core HA tier (one tightly crosslinked, one moderately crosslinked) from a single manufacturer to maximize rebate depth. Add one biostimulator if your patient base includes 45+ demographics or you want to differentiate on longevity. Consider a specialty product (SKINVIVE, Restylane Contour for jawline) if you have high case volume in that area. Avoid SKU sprawl: each additional product dilutes your volume rebate and increases inventory risk. Audit your case mix quarterly—which products move, which sit? Redirect budget to high-velocity items. Train your team on placement nuance: the same product in different hands yields different results and different patient satisfaction. Document outcomes by product and area; this data informs your next inventory decision and justifies premium pricing to patients. Your filler menu should reflect your patient population and clinical strengths, not the sales rep's latest pitch.